Is CABP2-Associated Hearing Loss (DFNB93) a Gene Therapy Target? Preclinical Progress and Patient Registry.
Barbara Vona, Bernd Wollnik, Nicola Strenzke...
https://pubmed.ncbi.nlm.nih.gov/40927552/Actively Recruiting
Led by University Medical Center Goettingen · Updated on 2026-01-27
100
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are collecting detailed information about individuals with hearing loss caused by genetic changes in the CABP2 gene. This observational study aims to support a natural history study by gathering genetic and clinical data to better understand CABP2-associated hearing impairment. The study is conducted under ethical guidelines and has approval from the Ethics Committee of the University Medical Center Goettingen. Participants in this registry undergo genetic testing and hearing assessments, including pure-tone and speech audiometry, which are the main diagnostic tests being studied. Secondary tests such as otoacoustic emission thresholds and auditory brainstem responses may also be collected. The study is available in both German and English to accommodate participants. During the study, participants provide consent for hearing tests and genetic information to be recorded and analyzed over a one-year period. Researchers monitor hearing function and genetic data to understand the progression and characteristics of CABP2-related hearing loss. Participation involves providing clinical and molecular genetic information to help support future research and treatment strategies.
CONDITIONS
CABP2 Patient Registry and Natural History Study
B
Barbara Vona, PhD
T
Tobias Moser, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
University Medical Center Goettingen
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 1 year according to participant consent
Participants undergo molecular genetic testing and audiometry to assess hearing impairment related to CABP2 variants.
Visits according to participant consent during the year
Duration - Up to 1 year according to participant consent
Participants are observed over time to monitor hearing function through audiometry and related tests.
Visits according to participant consent during the year
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Barbara Vona, Bernd Wollnik, Nicola Strenzke...
https://pubmed.ncbi.nlm.nih.gov/40927552/University Medical Center Goettingen
Lead Sponsor